A press release yesterday on the SEAS trial suggests that intensive cholesterol reduction with simvastatin and ezetimibe combination among patients with mild-moderate aortic stenosis (AS) does not reduce the rate of progression of AS but does appear to reduce the risk of coronary artery disease events. The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial is a randomized multinational study which determined the effects of intensive lipid (LDL cholesterol) lowering among patients with mild to moderate aortic stenosis.